Pharmacokinetics and Pharmacodynamics of Inhaled GLP-1 (MKC253): Proof-of-Concept Studies in Healthy Normal Volunteers and in Patients With Type 2 Diabetes

Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy

(2010) Mary Parks et al.   NEW ENGLAND JOURNAL OF MEDICINE

Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects

(2009) R E Steinert et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

TCF7L2 Variant rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action

(2009) D. T. Villareal et al.   DIABETES

Evaluation of novel particles as an inhalation system for GLP-1

(2009) A. Leone-Bay et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects

(2008) C Beglinger et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects

(2007) Aine M. McKillop et al.   DIABETES RESEARCH AND CLINICAL PRACTICE